| Literature DB >> 35049243 |
Zhiyan Jiang1,2,3.
Abstract
ABSTRACT: Myocardial ischemia reperfusion injury (MIRI) is a kind of complicated disease with an increasing incidence all over the world. Danshen was shown to exert therapeutic effect on MIRI. However, its chemical and pharmacological profiles remain to be elucidated. Network pharmacology was applied to characterize the mechanisms of Danshen on MIRI.The active compounds were screened from the online database according to their oral bioavailability and drug-likeness. The potential proteins of Danshen were collected from the TCMSP database, whereas the potential genes of MIRI were obtained from Gene Card database. The function of gene and pathways involved were researched by GO and KEGG enrichment analysis. The compounds-targets and protein-protein interaction networks were constructed by Cytoscape software. The affinity between active components and potential targets was detected by molecular docking simulation.A total of 202 compounds in Danshen were obtained, and 65 were further selected as active components for which conforming to criteria. Combined the network analysis and molecular docking simulation, the results firstly demonstrated that the effect of Danshen on MIRI may be realized through the targeting of vascular endothelial growth factor A, interleukin-6, and AKT1 by its active components tanshinone IIA, cryptotanshinone, and luteolin. The main regulatory pathways involved may include PI3K/ Akt signaling pathway, HIF-1 signaling pathway, and interleukin-17 signaling pathway. The present study firstly researched the mechanism of Danshen on MIRI based on network pharmacology.The results revealed the multicomponents and multi-targets effects of Danshen in the treatment of MIRI. Importantly, the study provides objective basis for further experimental research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 35049243 PMCID: PMC9191557 DOI: 10.1097/MD.0000000000028132
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1The detailed technical strategy of the present study.
Information of active compounds in Danshen with OB ≥30% and DL ≥0.18.
| Mol ID | Mol Name | MW | OB (%) | DL (%) |
| MOL001601 | 1,2,5,6-Tetrahydrotanshinone | 280.34 | 38.75 | 0.36 |
| MOL001659 | Poriferasterol | 412.77 | 43.83 | 0.76 |
| MOL001771 | Poriferast-5-en-3beta-ol | 414.79 | 36.91 | 0.75 |
| MOL001942 | Isoimperatorin | 270.3 | 45.46 | 0.23 |
| MOL002222 | Sugiol | 300.48 | 36.11 | 0.28 |
| MOL002651 | Dehydrotanshinone II A | 292.35 | 43.76 | 0.4 |
| MOL002776 | Baicalin | 446.39 | 40.12 | 0.75 |
| MOL000569 | Digallate | 322.24 | 61.85 | 0.26 |
| MOL000006 | Luteolin | 286.25 | 36.16 | 0.25 |
| MOL006824 | α-amyrin | 426.8 | 39.51 | 0.76 |
| MOL007036 | 5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-2,3-dihydrophenanthren-4-one | 298.41 | 33.77 | 0.29 |
| MOL007041 | 2-Isopropyl-8-methylphenanthrene-3,4-dione | 264.34 | 40.86 | 0.23 |
| MOL007045 | 3α-Hydroxytanshinone IIa | 310.37 | 44.93 | 0.44 |
| MOL007048 | (E)-3-[2-(3,4-Dihydroxyphenyl)-7-hydroxy-benzofuran-4-yl]acrylic acid | 312.29 | 48.24 | 0.31 |
| MOL007049 | 4-Methylenemiltirone | 266.36 | 34.35 | 0.23 |
| MOL007050 | 2-(4-Hydroxy-3-methoxyphenyl)-5-(3-hydroxypropyl)-7-methoxy-3-benzofurancarboxaldehyde | 356.4 | 62.78 | 0.4 |
| MOL007051 | 6-o-Syringyl-8-o-acetyl shanzhiside methyl ester | 628.64 | 46.69 | 0.71 |
| MOL007058 | Formyltanshinone | 290.28 | 73.44 | 0.42 |
| MOL007059 | 3-Beta-hydroxymethyllenetanshiquinone | 294.32 | 32.16 | 0.41 |
| MOL007061 | Methylenetanshinquinone | 278.32 | 37.07 | 0.36 |
| MOL007063 | Przewalskin a | 398.49 | 37.11 | 0.65 |
| MOL007064 | Przewalskin b | 330.46 | 110.32 | 0.44 |
| MOL007068 | Przewaquinone B | 292.3 | 62.24 | 0.41 |
| MOL007069 | Przewaquinone c | 296.34 | 55.74 | 0.4 |
| MOL007070 | (6S,7R)-6,7-Dihydroxy-1,6-dimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione | 312.34 | 41.31 | 0.45 |
| MOL007071 | Przewaquinone f | 312.34 | 40.31 | 0.46 |
| MOL007077 | Sclareol | 308.56 | 43.67 | 0.21 |
| MOL007079 | Tanshinaldehyde | 308.35 | 52.47 | 0.45 |
| MOL007081 | Danshenol B | 354.48 | 57.95 | 0.56 |
| MOL007082 | Danshenol A | 336.41 | 56.97 | 0.52 |
| MOL007085 | Salvilenone | 292.4 | 30.38 | 0.38 |
| MOL007088 | Cryptotanshinone | 296.39 | 52.34 | 0.4 |
| MOL007093 | Dan-shexinkum d | 336.41 | 38.88 | 0.55 |
| MOL007094 | Danshenspiroketallactone | 282.36 | 50.43 | 0.31 |
| MOL007098 | Deoxyneocryptotanshinone | 298.41 | 49.4 | 0.29 |
| MOL007100 | Dihydrotanshinlactone | 266.31 | 38.68 | 0.32 |
| MOL007101 | Dihydrotanshinone I | 278.32 | 45.04 | 0.36 |
| MOL007105 | Epidanshenspiroketallactone | 284.38 | 68.27 | 0.31 |
| MOL007107 | C09092 | 286.5 | 36.07 | 0.25 |
| MOL007108 | Isocryptotanshi-none | 296.39 | 54.98 | 0.39 |
| MOL007111 | Isotanshinone II | 294.37 | 49.92 | 0.4 |
| MOL007115 | Manool | 304.57 | 45.04 | 0.2 |
| MOL007118 | Microstegiol | 298.46 | 39.61 | 0.28 |
| MOL007119 | Miltionone I | 312.39 | 49.68 | 0.32 |
| MOL007120 | Miltionone II | 312.39 | 71.03 | 0.44 |
| MOL007121 | Miltipolone | 300.43 | 36.56 | 0.37 |
| MOL007122 | Miltirone | 282.41 | 38.76 | 0.25 |
| MOL007123 | Miltirone II | 272.32 | 44.95 | 0.24 |
| MOL007124 | Neocryptotanshinone ii | 270.35 | 39.46 | 0.23 |
| MOL007125 | Neocryptotanshinone | 314.41 | 52.49 | 0.32 |
| MOL007127 | 1-Methyl-8,9-dihydro-7H-naphtho[5,6-g]benzofuran-6,10,11-trione | 280.29 | 34.72 | 0.37 |
| MOL007130 | Prolithospermic acid | 314.31 | 64.37 | 0.31 |
| MOL007132 | (2R)-3-(3,4-Dihydroxyphenyl)-2-[(Z)-3-(3,4-dihydroxyphenyl)acryloyl]oxy-propionic acid | 360.34 | 109.38 | 0.35 |
| MOL007140 | (Z)-3-[2-[(E)-2-(3,4-Dihydroxyphenyl)vinyl]-3,4-dihydroxy-phenyl]acrylic acid | 314.31 | 88.54 | 0.26 |
| MOL007141 | Salvianolic acid g | 340.3 | 45.56 | 0.61 |
| MOL007142 | Salvianolic acid j | 538.49 | 43.38 | 0.72 |
| MOL007143 | Salvilenone I | 270.4 | 32.43 | 0.23 |
| MOL007145 | Salviolone | 268.38 | 31.72 | 0.24 |
| MOL007149 | NSC 122421 | 300.48 | 34.49 | 0.28 |
| MOL007150 | (6S)-6-Hydroxy-1-methyl-6-methylol-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-quinone | 312.34 | 75.39 | 0.46 |
| MOL007151 | Tanshindiol B | 312.34 | 42.67 | 0.45 |
| MOL007152 | Przewaquinone E | 312.34 | 42.85 | 0.45 |
| MOL007154 | Tanshinone iia | 294.37 | 49.89 | 0.4 |
| MOL007155 | (6S)-6-(Hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione | 310.37 | 65.26 | 0.45 |
| MOL007156 | Tanshinone VI | 296.34 | 45.64 | 0.3 |
Figure 2The venn diagram of “Danshen-MIRI” overlapping genes.
Targets of Danshen action on MIRI.
| No. | Target Symbol | Target Name | ID | Degree |
| 1 | AKT1 | RAC-alpha serine/threonine-protein kinase | 207 | 48 |
| 2 | IL-6 | Interleukin-6 | 3569 | 43 |
| 3 | VEGFA | Vascular endothelial growth factor A | 7422 | 42 |
| 4 | MAPK1 | Mitogen-activated protein kinase 14 | 1432 | 40 |
| 5 | STAT3 | Signal transducer and activator of transcription 3 | 6774 | 38 |
| 6 | CASP3 | Caspase-3 | 836 | 38 |
| 7 | PTGS2 | Prostaglandin G/H synthase 1 | 5742 | 38 |
| 8 | FOS | Proto-oncogene c-Fos | 2353 | 37 |
| 9 | MYC | Myc proto-oncogene protein | 4609 | 37 |
| 10 | JUN | Transcription factor AP-1 | 3725 | 35 |
| 11 | MAPK14 | Mitogen-activated protein kinase 14 | 1432 | 34 |
| 12 | BCL2L1 | Bcl-2-like protein 1 | 598 | 33 |
| 13 | CCND1 | G1/S-specific cyclin-D1 | 595 | 33 |
| 14 | IL-10 | Interleukin-10 | 3586 | 32 |
| 15 | MMP9 | Matrix metalloproteinase-9 | 4318 | 32 |
| 16 | RELA | Transcription factor p65 | 5970 | 31 |
| 17 | PPARG | Peroxisome proliferator activated receptor gamma | 5468 | 31 |
| 18 | ICAM1 | Intercellular adhesion molecule 1 | 3383 | 29 |
| 19 | IL-4 | Interleukin-4 | 3565 | 28 |
| 20 | MMP2 | 72 kDa type IV collagenase | 4313 | 28 |
| 21 | ESR1 | Estrogen receptor | 2099 | 28 |
| 22 | IL-2 | Interleukin-2 | 3558 | 27 |
| 23 | HMOX1 | Heme oxygenase 1 | 3162 | 27 |
| 24 | CASP9 | Caspase-9 | 842 | 27 |
| 25 | NR3C1 | Glucocorticoid receptor | 2908 | 26 |
| 26 | IFNG | Interferon gamma | 3458 | 25 |
| 27 | APP | Amyloid beta A4 protein | 351 | 25 |
| 28 | NFKBIA | NF-kappa-B inhibitor alpha | 4792 | 25 |
| 29 | CDKN1A | Cyclin-dependent kinase inhibitor 1 | 1026 | 25 |
| 30 | MDM2 | E3 ubiquitin-protein ligase Mdm2 | 4193 | 24 |
| 31 | NOS2 | Nitric oxide synthase, inducible | 4843 | 22 |
| 32 | MMP1 | Interstitial collagenase | 4312 | 21 |
| 33 | CD40LG | CD40 ligand | 959 | 20 |
| 34 | GSK3B | Glycogen synthase kinase-3 beta | 2932 | 19 |
| 35 | OPRM1 | Mu-type opioid receptor | 4988 | 15 |
| 36 | CASP7 | Caspase-7 | 840 | 14 |
| 37 | ADRB2 | Beta-2 adrenergic receptor | 154 | 14 |
| 38 | BIRC5 | Baculoviral IAP repeat-containing protein 5 | 332 | 12 |
| 39 | ACHE | Acetylcholinesterase | 43 | 12 |
| 40 | OPRD1 | Delta-type opioid receptor | 4985 | 11 |
| 41 | BCL2 | Apoptosis regulator Bcl-2 | 596 | 10 |
| 42 | PTGS1 | Prostaglandin G/H synthase 1 | 5742 | 10 |
| 43 | GSTP1 | Glutathione S-transferase P | 2950 | 9 |
| 44 | SLC6A4 | Sodium-dependent serotonin transporter | 6532 | 9 |
| 45 | HTR3A | 5-hydroxytryptamine receptor 3A | 3359 | 9 |
| 46 | ITGB3 | Integrin beta-3 | 3690 | 8 |
| 47 | EDNRA | Endothelin-1 receptor | 1909 | 7 |
| 48 | PTGES | Prostaglandin E synthase | 9536 | 7 |
| 49 | AKR1B1 | Aldose reductase | 231 | 7 |
| 50 | TYR | Tyrosinase | 7299 | 6 |
| 51 | SLC6A3 | Sodium-dependent dopamine transporter | 6531 | 6 |
| 52 | INSR | Insulin receptor | 3643 | 5 |
| 53 | PCNA | Proliferating cell nuclear antigen | 5111 | 5 |
| 54 | CHRM2 | Muscarinic acetylcholine receptor M2 | 1129 | 5 |
| 55 | FASN | Fatty acid synthase | 2194 | 4 |
| 56 | ECE1 | Endothelin-converting enzyme 1 | 1889 | 4 |
| 57 | SLC6A2 | Sodium-dependent noradrenaline transporter | 6530 | 3 |
| 58 | NR3C2 | Nuclear Receptor Subfamily 3 Group C Member 2 | 4306 | 3 |
| 59 | KCNH2 | Potassium voltage-gated channel subfamily H member 2 | 3757 | 2 |
| 60 | CHRM3 | Muscarinic acetylcholine receptor M3 | 1131 | 2 |
| 61 | SCN5A | Sodium channel protein type 5 subunit alpha | 6331 | 1 |
Figure 3Protein–protein interaction (PPI) network.
Figure 4“DS-compounds-MIRI-targets” (DCMT) network.
Figure 5Gene Ontology (GO) enrichment analysis. (A) Top 20 enriched GO terms selected from 6 common targets. (P-adjust value <.01) (B) A bubble plot to describe P-adjust value range of to 20 enriched results.
Figure 6KEGG pathway enrichment analysis. (A) Top 20 pathways from KEGG (P-adjust value <.01). (B) A bubble plot to describe p-adjust value range of to 20 pathways.
Figure 7Clustering analysis of signal pathways. The pathways were presented by circles. The main clusters are shown in bold labels.
Affinity of 3 active compounds of Danshen.
| Affinity, kcal/mol | AKT1 (1UNQ) | IL6 (1ALU) | VEGFA (3QTK) |
| Luteolin | −6.3 | −6.6 | −8.1 |
| Cryptotanshinone | −7.7 | −6.6 | −9.6 |
| Tanshinone IIA | −7.3 | −6.3 | −9.8 |
Figure 8Molecular docking between active compounds and main potential targets. (A) CPT act on AKT1; (B) Luteolin act on AKT1; (C) TSA act on AKT1; (D) CPT act on IL6; (E) Luteolin act on IL6; (F) TSA act on IL6; (G) CPT act on VEGFA; (H) Luteolin act on VEGFA; (I) TSA act on VEGFA. In every figure of molecular docking: a. holistic view of docking model; b. enlarged view of the docking section; c. 2D diagram of docking results. CPT = cryptotanshinone, TSA = tanshinone IIA, VEGFA = vascular endothelial growth factor A.